{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:00:03Z","timestamp":1780750803958,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1124\/dmd.113.051656","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T06:46:52Z","timestamp":1365058012000},"page":"1273-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["The Glucuronidation of R- and S-Lorazepam: Human Liver Microsomal Kinetics, UDP-Glucuronosyltransferase Enzyme Selectivity, and Inhibition by Drugs"],"prefix":"10.1016","volume":"41","author":[{"given":"Verawan","family":"Uchaipichat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuthamanee","family":"Suthisisang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.051656_bib1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1994.tb04304.x","article-title":"Decreased plasma protein binding of valproate in patients with acute head trauma","volume":"37","author":"Anderson","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1528-1157.1994.tb02937.x","article-title":"Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver","volume":"35","author":"Anderson","year":"1994","journal-title":"Epilepsia"},{"key":"10.1124\/dmd.113.051656_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jssc.200500268","article-title":"Analysis of lorazepam and its 30-glucuronide in human urine by capillary electrophoresis: evidence for the formation of two distinct diastereoisomeric glucuronides","volume":"29","author":"Baldacci","year":"2006","journal-title":"J Sep Sci"},{"key":"10.1124\/dmd.113.051656_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00008571-200011000-00002","article-title":"Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance","volume":"10","author":"Bhasker","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.051656_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib8","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/jps.2600831019","article-title":"A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate","volume":"83","author":"Bressolle","year":"1994","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.113.051656_bib9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","article-title":"Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers","volume":"77","author":"Chung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.051656_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","article-title":"Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects","volume":"83","author":"Chung","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.051656_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0076-6879(05)00007-8","article-title":"Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases","volume":"400","author":"Court","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.113.051656_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/03602530903209288","article-title":"Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system","volume":"42","author":"Court","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.113.051656_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.30.11.1257","article-title":"Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9","volume":"30","author":"Court","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1124\/jpet.104.067660","article-title":"UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver","volume":"310","author":"Court","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.051656_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.31.9.1125","article-title":"Evaluation of 3\u2032-azido-3\u2032-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism","volume":"31","author":"Court","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","article-title":"Clinical pharmacokinetics of ketoconazole","volume":"14","author":"Daneshmend","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.113.051656_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0920-1211(02)00252-8","article-title":"Oral\/intravenous maintenance dosing of valproate following intravenous loading: a simulation","volume":"53","author":"Dutta","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1124\/dmd.113.051656_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0378-4347(93)80211-L","article-title":"Identification and quantitation of intact diastereoisomeric benzodiazepine glucuronides in biological samples by high-performance liquid chromatography","volume":"613","author":"Franzelius","year":"1993","journal-title":"J Chromatogr"},{"key":"10.1124\/dmd.113.051656_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-198106020-00001","article-title":"Clinical pharmacokinetics of oxazepam and lorazepam","volume":"6","author":"Greenblatt","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.113.051656_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cpt1976203329","article-title":"Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam","volume":"20","author":"Greenblatt","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.051656_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","article-title":"Pharmacogenomics of human UDP-glucuronosyltransferase enzymes","volume":"3","author":"Guillemette","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.113.051656_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/03602530903210682","article-title":"UGT genomic diversity: beyond gene duplication","volume":"42","author":"Guillemette","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.113.051656_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2125.2009.03519.x","article-title":"Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion","volume":"68","author":"He","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/AAC.30.2.206","article-title":"Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers","volume":"30","author":"Huang","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.113.051656_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2003.02041.x","article-title":"Database analyses for the prediction of in vivo drug-drug interactions from in vitro data","volume":"57","author":"Ito","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3565(25)10294-2","article-title":"Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs","volume":"264","author":"Jin","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.051656_bib27","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1124\/dmd.109.028225","article-title":"Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10","volume":"37","author":"Kerdpin","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","article-title":"UDP-glucuronosyltransferases and clinical drug-drug interactions","volume":"106","author":"Kiang","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.113.051656_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib30","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/mol.107.037952","article-title":"Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4","volume":"72","author":"Kubota","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/seiz.2002.0590","article-title":"Coma probably induced by lorazepam-valproate interaction","volume":"11","author":"Lee","year":"2002","journal-title":"Seizure"},{"key":"10.1124\/dmd.113.051656_bib32","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.bcp.2006.12.021","article-title":"Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation","volume":"73","author":"Lewis","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9673(01)88948-2","article-title":"Resolution of enantiomeric lorazepam and its acyl and O-methyl derivatives and racemization kinetics of lorazepam enantiomers","volume":"535","author":"Lu","year":"1990","journal-title":"J Chromatogr"},{"key":"10.1124\/dmd.113.051656_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.113.051656_bib35","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1124\/dmd.111.041418","article-title":"Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9","volume":"39","author":"Manevski","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib36","doi-asserted-by":"crossref","first-page":"e54767","DOI":"10.1371\/journal.pone.0054767","article-title":"Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent","volume":"8","author":"Manevski","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1124\/dmd.113.051656_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.2000.00193.x","article-title":"Nonspecific binding of drugs to human liver microsomes","volume":"49","author":"McLure","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib38","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.113.051656_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.113.051656_bib41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0300-483X(02)00449-3","article-title":"Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance","volume":"182","author":"Miners","year":"2002","journal-title":"Toxicology"},{"key":"10.1124\/dmd.113.051656_bib42","series-title":"Enzyme and Transporter based drug-drug interactions","first-page":"217","article-title":"The in vitro characterization of inhibitory drug-drug interactions involving UDP-glucuronosyltransferase","author":"Miners","year":"2010"},{"key":"10.1124\/dmd.113.051656_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.051656_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0021-9673(96)01097-7","article-title":"On-column enantiomerization of 3-hydroxybenzodiazepines during chiral liquid chromatography with optical rotation detection","volume":"767","author":"Nishikawa","year":"1997","journal-title":"J Chromatography A"},{"key":"10.1124\/dmd.113.051656_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00008571-199510000-00004","article-title":"Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam","volume":"5","author":"Patel","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.051656_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-199502000-00005","article-title":"(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7","volume":"5","author":"Patel","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.051656_bib48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.051656_bib49","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.051656_bib51","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0090-9556(25)00105-9","article-title":"Diastereoisomeric glucuronides of oxazepam. Isolation and stereoselective enzymic hydrolysis","volume":"7","author":"Ruelius","year":"1979","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/j.1552-4604.1997.tb04322.x","article-title":"Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam","volume":"37","author":"Samara","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib54","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1111\/j.1365-2125.1979.tb00451.x","article-title":"Pharmacokinetics and metabolism of temazepam in man and several animal species","volume":"8","author":"Schwarz","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib55","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","article-title":"Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7","volume":"31","author":"Stone","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib56","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.106.009738","article-title":"Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode","volume":"34","author":"Takeda","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib58","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1124\/dmd.111.039727","article-title":"Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation","volume":"39","author":"Uchaipichat","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.051656_bib60","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/dmd.111.043117","article-title":"Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors","volume":"40","author":"Walsky","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.051656_bib61","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1158\/1078-0432.CCR-05-0703","article-title":"Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes","volume":"11","author":"Yong","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624097344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624097344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.051656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:09:13Z","timestamp":1739905753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624097344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0090955624097344"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.051656","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Glucuronidation of R- and S-Lorazepam: Human Liver Microsomal Kinetics, UDP-Glucuronosyltransferase Enzyme Selectivity, and Inhibition by Drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.051656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}